Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPMC Blueprint Medicines	$129.46	$128.90	$73.04 ▼ $129.65	$8.36B	0.89	1.55 million shs	N/A
EBS Emergent Biosolutions	$8.15 -1.0%	$7.71	$4.02 ▼ $12.73	$434.81M	2.04	956,560 shs	693,605 shs
EVTCY Evotec	$3.47 -0.3%	$3.82	$14.22 ▼ $26.57	$1.15B	0.98	2,407 shs	15,309 shs
PRGO Perrigo	$22.26 -1.3%	$25.00	$21.03 ▼ $30.93	$3.06B	0.48	1.42 million shs	1.33 million shs
TPTX Turning Point Therapeutics	$76.01	$75.83	$23.77 ▼ $82.20	$3.81B	-0.18	1.14 million shs	4,322 shs

7 Stocks to Ride The A.I. Megaboom

We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPMC Blueprint Medicines	0.00%	0.00%	0.00%	+0.94%	+45.62%
EBS Emergent Biosolutions	0.00%	+7.73%	-7.91%	+30.61%	+3.56%
EVTCY Evotec	0.00%	-0.29%	-9.16%	-18.74%	-1.98%
PRGO Perrigo	0.00%	-1.73%	-2.07%	-16.65%	-19.78%
TPTX Turning Point Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPMC Blueprint Medicines	$129.46	$128.90	$73.04 ▼ $129.65	$8.36B	0.89	1.55 million shs	N/A
EBS Emergent Biosolutions	$8.15 -1.0%	$7.71	$4.02 ▼ $12.73	$434.81M	2.04	956,560 shs	693,605 shs
EVTCY Evotec	$3.47 -0.3%	$3.82	$14.22 ▼ $26.57	$1.15B	0.98	2,407 shs	15,309 shs
PRGO Perrigo	$22.26 -1.3%	$25.00	$21.03 ▼ $30.93	$3.06B	0.48	1.42 million shs	1.33 million shs
TPTX Turning Point Therapeutics	$76.01	$75.83	$23.77 ▼ $82.20	$3.81B	-0.18	1.14 million shs	4,322 shs

7 Stocks to Ride The A.I. Megaboom

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPMC Blueprint Medicines	0.00%	0.00%	0.00%	+0.94%	+45.62%
EBS Emergent Biosolutions	0.00%	+7.73%	-7.91%	+30.61%	+3.56%
EVTCY Evotec	0.00%	-0.29%	-9.16%	-18.74%	-1.98%
PRGO Perrigo	0.00%	-1.73%	-2.07%	-16.65%	-19.78%
TPTX Turning Point Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BPMC Blueprint Medicines	2.11	Hold	$130.00	0.42% Upside
EBS Emergent Biosolutions	3.00	Buy	$13.50	65.64% Upside
EVTCY Evotec	0.00	N/A	N/A	N/A
PRGO Perrigo	2.40	Hold	$33.00	48.25% Upside
TPTX Turning Point Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest EBS, EVTCY, PRGO, BPMC, and TPTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2025	EBS Emergent Biosolutions	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00
8/7/2025	PRGO Perrigo	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$42.00 ➝ $40.00
8/7/2025	PRGO Perrigo	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$38.00 ➝ $35.00
6/17/2025	BPMC Blueprint Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$143.00 ➝ $129.00

(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BPMC Blueprint Medicines	$562.12M	14.87	N/A	N/A	$4.70 per share	27.54
EBS Emergent Biosolutions	$812.50M	0.54	$1.92 per share	4.24	$8.91 per share	0.91
EVTCY Evotec	$572.16M	2.00	$0.03 per share	105.53	$2.52 per share	1.38
PRGO Perrigo	$4.37B	0.70	$5.05 per share	4.41	$31.66 per share	0.70
TPTX Turning Point Therapeutics	$30.83M	123.46	N/A	N/A	$15.84 per share	4.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	199.17	N/A	-27.70%	-64.60%	-17.22%	10/28/2025 (Estimated)
EBS Emergent Biosolutions	-$190.60M	$2.45	3.33	3.94	N/A	16.38%	24.63%	8.97%	11/5/2025 (Estimated)
EVTCY Evotec	$7.14M	$0.41	8.46	∞	N/A	20.85%	16.02%	7.81%	N/A
PRGO Perrigo	-$171.80M	-$0.58	N/A	7.27	N/A	-1.86%	9.09%	3.96%	11/5/2025 (Estimated)
TPTX Turning Point Therapeutics	-$236.55M	-$6.90	N/A	N/A	N/A	N/A	-37.45%	-35.62%	N/A

Latest EBS, EVTCY, PRGO, BPMC, and TPTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2025	Q2 2025	EBS Emergent Biosolutions	-$0.26	$0.16	+$0.42	-$0.22	$148.55 million	$140.90 million
8/6/2025	Q2 2025	PRGO Perrigo	$0.59	$0.57	-$0.02	-$0.06	$1.08 billion	$1.06 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
EVTCY Evotec	N/A	N/A	N/A	N/A	N/A
PRGO Perrigo	$1.16	5.21%	N/A	N/A	23 Years
TPTX Turning Point Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest EBS, EVTCY, PRGO, BPMC, and TPTX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2025	PRGO Perrigo	quarterly	$0.29	4.88%	8/29/2025	8/29/2025	9/16/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BPMC Blueprint Medicines	1.01	2.80	2.75
EBS Emergent Biosolutions	1.25	5.66	3.00
EVTCY Evotec	0.53	2.57	2.50
PRGO Perrigo	0.81	2.32	1.24
TPTX Turning Point Therapeutics	N/A	16.83	16.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BPMC Blueprint Medicines	N/A
EBS Emergent Biosolutions	78.40%
EVTCY Evotec	N/A
PRGO Perrigo	95.91%
TPTX Turning Point Therapeutics	90.33%

Insider Ownership

Company	Insider Ownership
BPMC Blueprint Medicines	4.21%
EBS Emergent Biosolutions	1.20%
EVTCY Evotec	N/A
PRGO Perrigo	0.40%
TPTX Turning Point Therapeutics	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.86 million	Optionable
EBS Emergent Biosolutions	2,420	53.35 million	51.64 million	Optionable
EVTCY Evotec	4,200	330.22 million	N/A	Not Optionable
PRGO Perrigo	8,379	137.58 million	137.03 million	Optionable
TPTX Turning Point Therapeutics	250	50.07 million	45.77 million	Not Optionable

EBS, EVTCY, PRGO, BPMC, and TPTX Headlines

Recent News About These Companies

Turning Point Therapeutics Inc (TPTX) - Investing.com

June 26, 2025 | investing.com

BMS sets up Roche, Pfizer rivalry with Turning Point takeover

May 20, 2025 | pharmaphorum.comP

Digging Into Turning Point USA’s Role in the Trump 2024 Ground Game

October 8, 2024 | talkingpointsmemo.comT

Turning Point of Tampa Now In-Network with Blue Cross Blue Shield Insurance

September 29, 2024 | markets.businessinsider.com

Digital therapeutics at a turning point: What we heard at DTx East

September 14, 2024 | pharmaphorum.comP

PTC Therapeutics, Inc. (PTCT) Q2 2024 Earnings Call Transcript

August 9, 2024 | seekingalpha.com

TG Therapeutics, Inc. (TGTX) Q2 2024 Earnings Call Transcript

August 6, 2024 | seekingalpha.com

Viking Therapeutics, Inc. (VKTX) Q2 2024 Earnings Call Transcript

July 25, 2024 | seekingalpha.com

Glass System in Turning Point Residence

April 2, 2024 | archdaily.comA

Bid to remove prosecutors sets up turning point in Trump’s Georgia case

February 19, 2024 | politico.comP

Turning Point Brands Inc.

February 17, 2024 | wsj.com

Alzheimer’s: A Turning Point?

February 12, 2024 | bbc.co.uk

Turning Point Brands Inc (TPB)

February 10, 2024 | investing.com

Cormorant Asset Management, LP's Net Worth

February 10, 2024 | benzinga.com

Solving quadratic equations - Edexcel

January 15, 2024 | bbc.co.uk

COP15: A Turning Point for Investor Approaches to Biodiversity

December 19, 2023 | morningstar.comM

Turning Point USA: Are conservatives fighting back on campus?

December 16, 2023 | bbc.comB

BMS bet looking good as Augtyro approved in ROS1-positive NSCLC

November 16, 2023 | thepharmaletter.comT

PhD Study : Developing an AI-enabled point-of-care monitoring system to detect systemic concentration of therapeutics in blood

October 29, 2023 | ulster.ac.ukU

A Turning Point for Japan-US Climate Cooperation?

October 28, 2023 | thediplomat.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

EBS, EVTCY, PRGO, BPMC, and TPTX Company Descriptions

Blueprint Medicines NASDAQ:BPMC

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Emergent Biosolutions NYSE:EBS

$8.15 -0.08 (-0.97%)

Closing price 09/12/2025 03:59 PM Eastern

Extended Trading

$8.14 -0.01 (-0.06%)

As of 09/12/2025 07:13 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Evotec OTCMKTS:EVTCY

$3.47 -0.01 (-0.29%)

As of 09/12/2025

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Perrigo NYSE:PRGO

$22.26 -0.29 (-1.29%)

Closing price 09/12/2025 03:59 PM Eastern

Extended Trading

$22.27 +0.01 (+0.04%)

As of 09/12/2025 04:33 PM Eastern

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Turning Point Therapeutics NASDAQ:TPTX

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EBS, EVTCY, PRGO, BPMC, and TPTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EBS, EVTCY, PRGO, BPMC, and TPTX Earnings

Compare Dividends

Latest EBS, EVTCY, PRGO, BPMC, and TPTX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EBS, EVTCY, PRGO, BPMC, and TPTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EBS, EVTCY, PRGO, BPMC, and TPTX Company Descriptions

Blueprint Medicines NASDAQ:BPMC

Emergent Biosolutions NYSE:EBS

Evotec OTCMKTS:EVTCY

Perrigo NYSE:PRGO

Turning Point Therapeutics NASDAQ:TPTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools